Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. (Q34172042)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. |
scientific article |
Statements
1 reference
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. (English)
1 reference
Amy Heerema-McKenney
1 reference
Alan S Gamis
1 reference
Todd A Alonzo
1 reference
Soheil Meshinchi
1 reference
Lillian Sung
1 reference
Robert B Gerbing
1 reference
Susana C Raimondi
1 reference
Betsy A Hirsch
1 reference
Samir B Kahwash
1 reference
Laura Winter
1 reference
Kathleen Glick
1 reference
Stella M Davies
1 reference
Patti Byron
1 reference
Franklin O Smith
1 reference
Richard Aplenc
1 reference
1 September 2014
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference